Endostatin
- Generic Name
- Endostatin
- Drug Type
- Biotech
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: second-line chemotherapy
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Sun Yan
- Target Recruit Count
- 53
- Registration Number
- NCT03989830
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: PattozumabDrug: Ear particles
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
- Conditions
- Quality of Life
- Interventions
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03577392
- Locations
- 🇨🇳
Sichuan Provincial People Hospital, Chengdu, Sichuan, China
Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT03208335
- Locations
- 🇨🇳
Chinese PLA Gereral Hospital, Beijing, Beijing, China
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT03117335
- Locations
- 🇨🇳
Bengbu medical college affiliated hospital, Bengbu, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The first affiliated hospital, anhui medical university, Hefei, Anhui, China
Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 70
- Registration Number
- NCT03095079
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
- Conditions
- Adenocarcinoma of Lung
- Interventions
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02804646
- Locations
- 🇨🇳
Anhui provincial hospital, Hefei, Anhui, China
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
- Conditions
- Esophageal CancerEndostatin
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Hangzhou Cancer Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02745561
- Locations
- 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Endostar for Locally Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 96
- Registration Number
- NCT02636231
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The First Hospital of Gannan Medical University, GanZhou, Jiangxi, China
🇨🇳The First Affiliated Hospital of Clinical Medicine of G.D.P.U., Guangzhou, Guangdong, China
E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Guangzhou Double Bioproducts Co., Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT02630264
- Locations
- 🇨🇳
Guangzhou DB, Gaungzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.